A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving patient experience, and the underlying customer marks are unusually stout.
Customer Willingness Matters More Than Award Hardware
KLAS reported that 96% of NextPatient customers would buy the software again, gave executive involvement an A+, and recorded a 93.3 out of 100 overall performance score. Those figures are not revenue, margins, retention cohorts, or cash flow. Anybody pretending otherwise is selling fog. Still, a repurchase figure that high is worth attention in healthcare technology, where lousy implementations can leave customers grumbling for years and switching systems is a miserable chore.
The distinction matters. Healthcare software buyers do not casually replace tools tied to scheduling, communications, check-in, payment collection, and electronic health records. A platform that fits daily workflow can become stubbornly hard to dislodge. That does not guarantee NextPatient has a durable moat, but it does suggest the company has avoided a common trap: building something flashy that staff resent using once the sales demo is over.
Specialty Practices Have Little Room for Friction
NextPatient is aimed at specialty medical practices, a market with its own set of bruises. These offices must keep appointments filled, handle patient questions, manage no-shows and recalls, and do it with limited administrative capacity. The company says its platform automates online self-scheduling, waitlists, reminders, digital check-in, payments, and recalls using the scheduling rules a practice already follows. That is the right battlefield. Nobody in a busy office wants a shiny new workflow bolted on top of the old mess.
Its direct integration with EHR and practice-management systems is equally important. Integration claims are cheap as wallpaper, so investors and operators should always press for specifics: how long deployment takes, how much staff training is required, and whether the rules actually hold up across different specialties. Those details are absent here. But the KLAS scores indicate customers believe the implementation is producing the intended result.
- 96% of surveyed customers said they would buy NextPatient again.
- KLAS gave the company an A+ for executive involvement.
- All reported outcomes were achieved, according to the KLAS findings.
- More than 8,000 providers in the United States use the platform.
The Fine Print Is Where This Story Still Needs Work
The announcement says 100% of outcomes were achieved. Fine, but that phrase needs a little daylight around it. Outcomes depend on what was measured, over what period, and for which customers. It is encouraging evidence, not a substitute for knowing renewal rates, customer concentration, pricing, implementation costs, or the economics of supporting thousands of providers. There is no financial disclosure in this recognition, and there should not be any confusion about that.
Still, this is a cleaner signal than the usual healthcare-tech chest beating. KLAS has been gathering provider and payer feedback since 1996, and its Emerging Solutions report evaluates offerings against healthcare’s Quadruple Aim: patient outcomes, cost of care, patient experience, and clinician experience. NextPatient’s top-five placement specifically for patient experience is meaningful because a smooth patient journey can also reduce the administrative drag that burns out staff.
Voice AI Is Interesting, but It Is Not the Main Event Yet
NextPatient also says its Voice AI product is in beta and operates on the same scheduling rules as the core platform. That could be sensible. One configuration instead of separate rules for humans and automation is the sort of boring architectural choice that prevents headaches later. But beta means beta. The software has not yet earned the right to carry the investment argument on its back.
Co-founder Kyle Morham accepted the recognition at the KLAS HLTH 2026 ceremony on November 17, one day before the November 18 announcement. The award itself will not transform the business. What it can do is give specialty practices a credible outside reference when they are weighing vendors. In healthcare IT, trust travels slowly. A strong customer score from a recognized evaluator can move the conversation along, and that is nothing to sneer at.
My read is restrained but favorable: NextPatient appears to have found a practical niche where workflow fit counts more than gimmicks. The next proof points should be adoption depth, renewals, and whether the company can keep service quality intact as its provider base expands. For now, the customer feedback is a solid green flag—not a blank check.